CPIC 2026 | Vaccine Innovation & Global Expansion Session

CPIC 2026 | Vaccine Innovation & Global Expansion Session – Agenda Debut

Update time:

2026-05-28 15:04

Reads:

How will AI and automation reshape the R&D paradigm for mRNA drugs? Where is the breakthrough point for the multibillion-dollar pneumonia vaccine market? How can the innovation incubation of multivalent combination vaccines be aligned with regulatory expectations? And how far is China‘s vaccine industry from evolving from a product exporter to a global brand?

The answers to these questions await at the Vaccine Innovation and Global Expansion Session — the full agenda of which is released today. This session brings together frontline practitioners from across the vaccine field to engage in in-depth discussions on technology transformation, product breakthroughs, innovation incubation, and global strategy.

July 22–24, Shanghai National Exhibition and Convention Center — join the pioneers of China’s vaccine industry as we explore the next horizon of innovation and global expansion.

Agenda

Engine Reimagined: The mRNA Drug R&D Revolution Driven by AI and Automation
Ying Bo: Founder, Chairman and CEO, AbogenBio

The Breakthrough Direction for Pneumococcal Vaccines
Zhu Tao: Director and CSO, CanSino Biologics Inc.

AI-Enabled Innovation Incubation of Multivalent Combination Vaccines
Hou Jian: CEO, Xinzhi Biotech

Panel Discussion: China Vaccine Innovation and Global Expansion
Liao Xiang (Moderator): Director, Clover Biopharmaceuticals, Ltd.
Zhang Jiguo: President, Vaccine Business Unit, Fosun Pharma
Wu Hongbo: General Manager, Vaccine Business Unit, China National Biotec Group
Dong Shaozhong: Vice Chairman, Walvax Biotechnology Co., Ltd.
Meng Weining: Deputy General Manager and Head of International Business, Sinovac Biotech Ltd.

Which Chinese New Drugs Are Poised to Take ASCO by Storm?

CPIC 2026 | Over 1000 companies have registered! Last 5 days for 30% off registration, miss it and the price will rise